Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000472 |
The Thrombolysis in Myocardial Ischemia Trial (TIMI III) focused on unstable angina and non-Q-wave myocardial infarction. The trial was designed to determine by coronary arteriography the incidence of coronary thrombi in these conditions and the response of these thrombi to tissue-type plasminogen activator (t-PA) in TIMI IIIA and the effects of thrombolytic therapy and of an early invasive strategy on clinical outcome in TIMI IIIB. There was also a registry with two components. A roster enumerated all patients with unstable angina or non-Q-wave myocardial infarction enrolled at cooperating hospitals. From the roster, a study population of 1,893 subjects was selected and followed prospectively for the year to determine incidence of death or myocardial infarction.
Condition | Intervention | Phase |
---|---|---|
Angina Pectoris Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Infarction Myocardial Ischemia |
Drug: tissue plasminogen activator Drug: heparin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind |
Ages Eligible for Study: | 21 Years to 76 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women, ages 21 to 76, with unstable angina or non-Q-wave myocardial infarction.
Study ID Numbers: | 61 |
Study First Received: | October 27, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000472 |
Health Authority: | United States: Federal Government |
Arterial Occlusive Diseases Heart Diseases Myocardial Ischemia Angina Pectoris Vascular Diseases Tissue Plasminogen Activator Pain Ischemia Arteriosclerosis Calcium heparin |
Chest Pain Coronary Disease Signs and Symptoms Necrosis Infarction Plasminogen Heparin Myocardial Infarction Coronary Artery Disease |
Fibrin Modulating Agents Pathologic Processes Molecular Mechanisms of Pharmacological Action Therapeutic Uses Hematologic Agents |
Fibrinolytic Agents Cardiovascular Diseases Cardiovascular Agents Pharmacologic Actions |